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Cardiovascular disease (CVD) is the most common cause of death among men
and women in the United States. Since 1900 it has been the number one killer in the
country, with the exception of 1918 (AHA, 2001). CVD includes hypertension,
coronary heart disease (myocardial infarction and angina pectoris), stroke, congenital
cardiovascular defects, and congestive heart failure. On average, one death occurs
every 33 seconds from CVD. This disease claims approximately 150,000 lives, under
the age of 65, each year. Out of all the cardiovascular diseases, coronary heart
disease (CHD) is the single largest killer of Americans (AHA, 2001).
It is estimated that CVD will cost $329.2 billion in the year 2002. This amount
includes direct (i.e. health expenditures, medications, etc.) and indirect costs (i.e. lost
productivity). CHD alone is predicted to cost the economy $111.8 billion in 2002
(AHA, 2001).
Risk factors for CVD are numerous and include smoking, elevated low-density
lipoprotein (LDL), high triglycerides (TG), low high-density lipoprotein (HDL),
elevated lipoprotein (a) (Lp(a», oxidative stress, hypertension, high fat diet, physical
inactivity, obesity, diabetes mellitus, and postmenopausal status without hormone
replacement therapy (HRT) (Davidson & Maki, 1998). Between 1988-1994, 61 % of
American men and 51 % of American women were found to be overweight [body
mass index (BMI) ~ 25.0], compared to 1960-1962 when only 49.1 % and 40.2%
respectively were found to be overweight (AHA, 2001).
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Research has revealed that after the age of 50 more women have high cholesterol
than men. Forty-eight percent of American men and 43.3% of American women age
20 years and older were found to have elevated LDL levels. In the same age group
39% of American men and 14.9% of American women were found to have HDL
levels s 40 mg/dl (AHA, 2001).
After the onset of menopause CHD risk appears to increase 2-3 times in women
(AHA, 2001). Ovarian honnones including estradiol (E2) and estrone (El ) levels
drastically decrease at the onset of menopause (Mosca, 2000; von Holst, 1994).
Decreased E2 production has been linked to an increase in total cholesterol, LDL-
cholesterol, and TG (Schwab, 2000). However, the true relationship between
estrogen production and CHD in postmenopausal women remains unclear. Studies
have shown that estrogens decrease CHD risk by acting directly on the vascular wall
and decreasing the rate of atherosclerotic progression (Tremollieres et aI., 1999).
One of the most common methods used to treat symptoms of menopause is
exogenous estrogen in the fonn of HRT. Research has shown HRT to be beneficial
for postmenopausal women as far as improving lipid profiles and decreasing the risk
of osteoporosis. However, certain risks have been associated with HRT. Some
studies have shown that HRT might increase the risk of breast and/or endometrial
cancer, and thrombosis (Greendale et aI., 1999). As a result some women might not
be willing or able to receive HRT.
An alternative to HRT, still undergoing research, is selective estrogen receptor
modulators (SERMs), e.g. raloxifene and tamoxifen. SERMs appear to have
cardiovascular benefits for postmenopausal women with less risk of developing
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honnone sensitive cancers as seen with HRT. However, SERMs appear to be less
effective in treating some symptoms of menopause, such as hot flashes (Anthony et
aI., 2001). SERMs continue to remain controversial as far as bene~ting the
cardiovascular system (Roe et aI., 2000; Valk-de Roo et aI., 1999). As a result,
postmenopausal women continue to seek alternative and more natural ways to
decrease CHD risk associated with menopause. Animal and human research has
shown that bioactive constituents of certain foods such as polyphenolic compounds
and fiber are beneficial in decreasing CHD (Arjmandi et aI., 1992; Lucas et aI., 2000;
Tinker et aI., 1991; Wolk et aI., 1999). Among fruits, dried plums are an excellent
source of fiber and polyphenolic compounds (Donovan et aI., 1998; Stacewicz-
Sapuntzakis et aI., 2001); however, the cholesterol-lowering properties of dried plum
in postmenopausal women have not been investigated.
Dried plums, also known as prunes, (Prunus domestica L.) continue to show
promising effects in decreasing some of the risks associated with heart disease. Dried
plums are a good source of fiber, flavonoids, and phenols, which research has shown
to possibly have a cardioprotective effect (Donovan et aI., 1998; Lucas et aI., 2000;
Stacewicz-Sapuntzakis et aI., 2001; Tinker et aI., 1991). The purpose of this study is
to detennine if a relationship exists between dried plum intake and blood lipid levels
in postmenopausal women.
The hypothesis of this study is that regular consumption of dried plums by
postmenopausal women improves their blood lipid profiles including cholesterol and
triglycerides.
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The objectives of this study are:
1. To determine if consumption of 100 grams of dried plums versus 75
grams of dried apples daily will decrease total- and low density
lipoprotein (LDL)-cholesterol, TG, Lp(a), apolipoprotein B (Apo B)
and c-reactive protein (CRP).
2. To identify if daily intake of dried plums or dried apples increases




IMPACT OF CORONARY HEART DISEASE IN THE UNITED STATES
Coronary heart disease (CHD), also known as coronary artery disease, is a
condition that decreases blood flow through the coronary arteries to the heart muscle.
Sclerosis and thrombosis are conditions that can result in CHD. Atherosclerosis occurs
by forming fatty streaks, which progress to advanced lesions possibly causing acute
coronary events, such as myocardial infarction or angina pectoris (Davidson & Maki,
1998).
CHD IS the most prevalent killer among American men and women.
Approximately every minute an American's life is taken by CHD. CHD not only affects
people, but also negatively impacts the economy. The Social Security Administration
spends about 19% of disability allowances on CHD. Medicare beneficiaries were paid
$10.6 billion in 1998 for CHD alone. More than 12 million people today have had a
heart attack and/or a chest pain episode. On average a woman or man's first heart attack
will occur at 70.4 years old and 65.8 years old respectively (AHA, 2002).
The National Heart, Lung, and Blood Institute's (NHLBI) Framingham Heart
Study is one of the leading cardiovascular disease studies. Part of the Framingham
Heart Study found that in a study group less than 75 years old, more than half of the
cardiovascular events that occurred were caused by CHD. At the age of 40, men have a
49% lifetime risk of developing CHD and women have a 32% risk (AHA, 2002). A
cohort of 2,873 women who took part in the Framingham study were followed up 24
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years after the initiation of the study. Postmenopausal women experienced significantly
more coronary events than premenopausal women. The same study also observed that
after the onset of menopause a woman is 2-3 times more likely to develop CHD
compared to premenopausal women in the same age group (Gordon et aI., 1978). This
study demonstrated that menopause is a risk factor for CHD. This research has raised
many questions on the relationship between menopause and CHD leaving researchers
seeking ways to find the exact mechanisms menopause has on CHD and ways to decrease
CHD risk factors associated with menopause.
RISK FACTORS RELATED TO CORONARY HEART DISEASE
IN POSTMENOPAUSAL WOMEN
Common risk factors associated with CHD include: elevated TC (>200 mg/dL),
decreased HDL «35 mg/dL), increased TG, obesity, high fat/cholesterol diet, cigarette
smoking, hypertension, diabetes mellitus, physical inactivity, age (male >45 years old
and women >55) and gender (Davidson & Maki, 1998). Women increase their risk for
CHD after menopause when HRT is not initiated (Dallongeville et aI., 1995; Tremollieres
et aI., 1999).
Menopause occurs when ovanan follicular activity ceases along with
menstruation; therefore, decreasing endogenous estrogen levels (Burger et aI., 2002). An
increase in CHD risk has been associated with both, natural and surgical menopause
(Hjortland et aI., 1976; Kannel W, 1987). After the onset of menopause the decrease in
estrogen production is believed to directly impact CHD risk. One proposed mechanism
of how estrogen is cardioprotective is by directly affecting the vascular wall (Mendelsohn
& Karas, 1994). Another study found that menopause decreases the activity of
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antioxidant enzymes, which increases CAD risk (Krstevska et aI., 2001). Menopause and
its effect on CHD risk continues to remain a controversial issue (Do et aI., 2000;
Rossouw, 2000).
Over 100,000,000 Americans, 20 years or older, are considered overweight and
the number continues to increase worldwide (AHA, 2002). Obesity is linked to other
CHD risk factors, such as diabetes, physical inactivity, elevated TG and hypertension
(Campos et aI., 1991; Cordero-MacIntyre et aI., 2000; Schulte et aI., 1999).
Hypertension also increases endothelial cell damage, further increasing a person's
risk for CHD (Davidson & Maki, 1998). When comparing postmenopausal women to
men and premenopausal women in the same age group, postmenopausal women showed
a greater increase in blood pressure (Bulliyya, 2001). Studies have shown mixed results
on systolic and diastolic blood pressure among postmenopausal women (Bonithon-Kopp,
1990; Dallongeville et aI., 1995). Controversy still remains if blood pressure is affected
by menopause or if it is age related (Franklin et aI., 2001; Rossouw, 2000).
A French study including 1,684 women not on HRT, found that menopause
increased blood pressure, TC, LDL-cholesterol, TG, apo B, and decreased HDL-
cholesterol. This study also reevaluated the data by restricting the data to women age 45-
55 years old to see if age unfavorably influenced CHD risk over menopause, menopause
continued to have a greater impact on CHD than age (Tremollieres et aI., 1999).
Other CHD risk factors to consider are apo A-I, apo Band Lp(a). Apo A-I is the
major apolipoprotein of HDL-cholesterol and apo B is the major apolipoprotein of LDL-
cholesterol (Gardner et aI., 2000). Menopause was found to significantly increase apo
A-I and apo B; however, after age, BMI, and smoking status were controlled for, apo B
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remained significantly higher when comparing premenopausal to postmenopausal women
(Bonithon-Kopp et aI., 1990; Dallongeville et a!., 1995). Tremollieres et aL (1999), also
demonstrated that apo B increased with menopause; however, apo A-I levels did not
sigtllficantly change. Dallongeville et al. (1995), also found menopause negatively
influenced total cholesterol, triglycerides, apo B, apo A-I, and diastolic blood pressure
independent of age, BMI, glycemia, smoking, alcohol intake, exercise and parity. The
Framingham offspring study found a direct relationship between age and LDL-
cholesterol and apo B, after adjusting for age and BMI. LDL-cholesterol and apo B
remained higher in postmenopausal women when compared to premenopausal women,
thus proposing a hormonal effect (Schaefer et aI., 1994).
It is beneficial to evaluate the entire lipoprotein profile instead of just the Te
level, which can incorrectly categorize a person's CHD risk (Branchi et aI., 1994). It is
still unclear if menopause directly alters HDL-choiesteroi. One study comparing pre-,
peri-, and postmenopausal women found postmenopausal women had higher HDL-
cholesterol levels than premenopausal women. TC, LDL-cholesterol and Lp(a) were
higher in postmenopausal women compared to premenopausal women; therefore, the
authors concluded that HDL-cholesterol levels might be affected more by age than
menopause (Kim et aI., 2000). Do et ai. (2000) followed women three years before and
after their final menstrual period. HDL-cholesterol significantly decreased after the onset
of menopause. In fact, a slight increase in HDL-cholesterol was observed about one year
before menopause, then the greatest decrease in HDL-cholesterol was observed about one
year after menopause. Age was found to significantly increase TG, diastolic blood
pressure, BMI, and LDL cholesterol.
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The impact of menopause on lipoproteins like HDL-cholesterol remains
unanswered. Some studies have concluded that menopause has a detrimental affect on
TG (Dallongeville et aI., 1995; Kim et aI., 2000; Tremollieres et aI., 1999) and others
have shown no effect on TG (Do et aI., 2000; Pasquali et aI., 1997).
Other CHD risk factors that continue to be researched are Lp(a), homocysteine
and C-reactive protein (CRP). Lp(a) is structurally similar to LDL-cholesterol and is
considered an atherogenic particle; therefore, a CHD risk (Jenner et aI., 1993). Several
studies have found a relationship between Lp(a) levels and menopause (Kim et aI., 2000;
Sposito et aI., 2001).
More recently elevated homocysteine has been linked to heart disease. The amino
acid homocysteine results from dietary protein metabolism. Homocysteine forms as a
result of the conversion of methionine to cysteine. This process involves folic acid,
vitamin B6, and vitamin BI2 (Malinow et aI., 1999). One way homocysteine increases
CHD risk is by negatively affecting endothelial cells (Kanam et aI., 1999; Stamler et aI.,
1993; Woo et aI., 1997). Hyperhomocysteinemia has also been linked to increased
platelet accumulation leading to CHD (McCully et aI., 1987; Stamler et aI., 1993).
Elevated homocysteine levels were found in healthy postmenopausal women; therefore,
increasing their CHD risk (Knekt et aI., 2001; Ridker et aI., 1999). However,
homocysteine studies involving women are limited. Increased homocysteine levels were
associated with low folic acid, vitamin B6 and vitamin B12 intakes in elderly men and
women in the Framingham Study (Selhub et aI., 1995). Many research studies have
shown significant decreases in homocysteine by increasing folic acid, vitamin B6 and
vitamin B12 intake (Jacques et aI., 1999; Malinow et aI., 1998; Rimm et aI., 1998).
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Another CHD risk factor is CRP, which is a vascular inflammation marker.
Inflammation can result from bacterial infection, trauma and/or tissue damage (Jialal &
Devaraj, 2001; Koenig et aI., 1999), which can promote atherosclerosis. When
evaluating CHD risk one must take into consideration all risk factors including lipid
levels and lifestyle factors.
PREVENTION AND TREATMENT OF CORONARY HEART DISEASE IN WOMEN
DIET AND EXERCISE
Lifestyle modification is the first step to decrease CHD risk. Modifications such
as a low fat diet, high fiber intake, physical activity, smoking cessation and an increase in
dietary omega-3 fatty acid intake have all been shown to decrease CHD risk.
The American Heart Association (AHA) and National Cholesterol Education
Program (NCEP) recommend two different diets to treat hypercholesterolemia,
depending on the severity of the individual (AHA Scientific Position, 2002). Step I and
Step II diets are listed below:
NUTRIENT STEP I DIET STEP II DIET
Total Fat 30% or less 30% or less
Saturated Fat 7-100/0 Less than 7%
Polyunsaturated Fat Up to 100/0 Up to 10%
Monounsaturated Fat Up to 15% Up to 15%
Carbohydrate 55% or more 550/0 or more
Protein Approx.15% Approx. 150/0
Cholesterol Less than 300mglday Less than 200mglday
Total Calories To achieve and maintain To achieve and maintain
desired weight desired weight
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In October 2000 the AHA decided to no longer use the Step I and Step II diets, instead
they recommend maintaining appropriate body weight, overall healthy eating pattern,
desirable cholesterol profile and desirable blood pressure for the general population.
Therefore, it emphasizes the components of food and not percentages of these
components (AHA Scientific Position, 2002).
There have been many research studies demonstrating the effectiveness of the
AHA Step I and II diets. By following a Step I or Step II diet a person can significantly
reduce their TC and LDL-cholesterollevels (Bunyard et aI., 2002; DenIce, 1994; Geil et
aI., 1995). Physical activity further benefits a person's lipid profile when added to a low-
fat and low-cholesterol diet (Stampfer et aI., 2000; Stefanick et aI., 1998). The effects of
the AHA diets and physical activity on HDL-cholesterol are mixed (Barnard, 1991;
Schuler et aI., 1992; Stefanick et a!., 1998).
Cholesterol lowering diets also include increased intake of fiber, monounsaturated
fatty acids (MUFAs) and polyunsaturated fatty acids (PUFAs). Good sources ofMUFAs
are olive, canola and peanut oil. PUFAs are found in com, safflower and soybean oil.
MUFAs and PUFAs, when combined or used independently, reduce LDL-cholesterol
particle size (Kratz et aI., 2002). A diet rich in PUFAs was found to decrease TC, LDL-
cholesterol and TG, but had no effect on HDL-cholesterol (Wagner et aI., 2001). MUFAs
have also shown benefits on decreasing LDL-cholesterol susceptibility to oxidation
(Kratz et aI., 2002). This is Important for postmenopausal women due to research
showing that menopause decreases antioxidant enzyme activity (Krstevska et aI., 2001).
Increasing fiber intake, especially soluble fiber, is beneficial in decreasing
cholesterol levels. Human and animal studies have revealed that soluble fiber, such as
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pectin or guar gum, significantly reduce TC and LDL-cholesterollevels (Atjrnandi et aI.,
1992; Knopp et aI., 1999). In a National Health and Nutrition Examination Survey
epidemiological follow-up' study, dietary fiber was found to significantly decrease eHD
risk in men and women (Bazzano et aI., 2001). Hunninghake et ai. (1994) found a-S%
decrease in TC and 9% decrease in LDL-cholesterol when supplementing 20 g of fiber
(guar gum, pectin, soy, pea, com bran) per day.
Current research is focusing on functional foods and their effect on serum
cholesterol levels. A few of these functional foods are soy protein, flaxseed, oatmeal,
garlic, and grapes (Frankel et aI., 1998; Stein et aI., 1999). However, the effect of dried
plums on cholesterol has not been adequately investigated and was the focus of this
study.
CHOLESTEROL-LOWERING DRUGS
Lifestyle changes do not always succeed in improving lipid profiles. There are a
variety of drugs available that can improve lipid profiles by different mechanisms. The
most common and widely used drugs are the statins also known as 3-hydroxy-3-
methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors. These drugs decrease
LDL-cholesterol and TG and possibly increase HDL-cholesterol by inhibiting the rate of
cholesterol synthesis (Branchi et aI., 2001; Kuncl & Nelson, 2000). Numerous studies
have demonstrated the effecriveness of statins on improving lipid profiles by decreasing
TC and LDL-cholesterol, and increasing HDL-cholesterol (Pederson et aI., 1996; Pfeffer
et aI., 1995; Shepherd et aI., 1995). Even though statins are highly effective on lipids
they can be expensive and interact with other medications (Chong et aI., 2001).
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Another common drug used to improve lipids is bile acid sequestrants (inhibitors
of bile acid transport). Bile acid sequestrants bind bile acids in the gut preventing
enterohepatic cycling. Therefore, forcing the liver to make replacement bile acids from
cholesterol, which increases LDL receptors drawing LDL-cholesterol from serum
(Brown,2001). Research has found bile acid sequestrants to decrease TC and LDL-
cholesterol (Rifkind, 1984); however, increases in TG levels have been observed
(O'Brien et aI., 1990). Bile acid sequestrants can cause gastrointestinal disturbances
and can be more effective when combined with HMG-CoA reductase inhibitors (Kuncl
& Nelson, 2000).
Another possible option for people who cannot tolerate HMG-CoA reductase
inhibitors is niacin. Niacin is used to decrease LDL-cholesterol and TG along with
increasing HDL-cholesterol, but has been known to cause a number of adverse effects.
Niacin stimulates the release of histamine and prostaglandins, which can cause itching
and flushed skin. Niacin can be used concurrently with HMG-CoA reductase inhibitors
or bile acid sequestrants. Fibric acid derivatives increase HDL-cholesterol and decrease
TG; however, they have little effect on LDL-choiesteroi. Derivatives of fibric acid are
generally used to treat hypertriglyceridemia to prevent pancreatitis (Kuncl & Nelson,
2000).
HORMONE REPLACEMENT THERAPY
HRT may improve CHD risk in postmenopausal women by improving their lipid
profiles. Several methods and combinations ofhonnones are administered to treat
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menopausal symptoms. Estrogen is commonly given in combination with progestin or
medroxyprogesterone to decrease possible side effects of estrogen alone.
There are several proposed mechanisms ofhow estrogen decreases CHD risk.
Estrogen replacement therapy (ERT) has been shown to have antioxidant properties-;
therefore, decreasing oxidation ofLDL-cholesterol resulting in decreased eHD risk
(Krstevska et aI., 2001; Shwaery et aI., 1997). One mechanism ofHRT benefiting eHD
risk is by vasorelaxation of the arteries by increasing nitric oxide release from endothelial
cells resulting in a decrease in blood pressure (Cicinelli et aI., 1998; Collins et aI., 1994).
Animal and human studies have shown that estrogen can reduce coronary artery plaques,
which can develop into atherosclerosis (Adams et aI., 1997; Nathan & Chaudhuri, 1997).
Plaques forming inside vessel walls can form a thrombus resulting in a heart attack or
stroke (AHA, 2001). Atherosclerosis accounts for almost three-fourths of all CVD
deaths. Estrogen has been shown to decrease atherosclerotic progression by lowering
lipid levels (Dallongeville et aI., 1995).
Research has shown that HRT has beneficial effects on CHD and is able to
improve lipid profiles. Dallongeville et ai. (1995) found that using estrogen combined
with progestin resulted in significant decreases in TC, LDL-cholesterol, TG, apo B, and
systolic and diastolic blood pressure. Another study evaluated the effects ofERT and
combined HRT on surgical and natural menopause in over a thousand women. In this
study estrogen only therapy resulted in significant decreases in TC, LDL-cholesterol and
an increase in HDL-cholesterol. When conjugated equine estrogen was compared to
transdermal estrogen, the transdermal method increased TG and HDL more than ERT
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alone (Gokmen & Eyi, 1999). HRT is a highly researched topic since conflicting results
ofHRT and their beneficial affects on lipids have been found.
Three of the largest trials involving HRT and lipids are the Estrogen Replacement
and Atherosclerosis study (ERA), the Heart and Estrogen/Progestin Replacement study
(HERS) and the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. HERS
recruited 2763 postmenopausal women less than 80 years old who had a history ofCHD.
Participants were randomized into two groups: conjugated equine estrogen plus
medroxyprogesterone acetate or placebo. After about four years on treatment no
significant differences were found between the two groups, in fact an increase in
thromboembolism occurred in the estrogen plus progesterone group. These results may
have been related to prothrombotic effects of estrogen (Grady et aI., 2000; Hulley et aI.,
1998). The ERA study was a randomized, placebo-controlled, double blind trial
comparing estrogen with or without progestin versus placebo. Three hundred and nine
postmenopausal women with atherosclerosis fronl five different sites took part in the
study. Approximately three years after initiation of the study no benefit was found on the
progression of atherosclerosis (Herrington & Klein, 2001). The PEPI trial was a
randomized, double blinded, placebo controlled clinical trial that also evaluated the
effects ofERT with and without progestin. The study evaluated three different progestin
regimens on 847 postmenopausal women. Improvements in LDL-cholesterol and HDL-
cholesterol levels were found. In fact women receiving estrogen alone showed a greater
increase in HDL-cholesterollevels than women on one of the estrogen/progestin
combinations (Barrett-Conner et aI., 1997). Another study evaluating CHD risk factors
and HRT involved 1746 postmenopausal women of which 369 were currently taking
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combined (estrogen and progestin) HRT. Postmenopausal women taking combined
hormone therapy had significantly lower serum TC, TG, apo B, and systolic/diastolic
blood pressure when compared to non-HRT users (Dallongeville et aI., 1995).
Most women seek HRT to relieve hot flashes and discol1tinue therapy when th.ey
no longer have hot flashes. More highly educated, Caucasian females are more likely to
use HRT; therefore, some studies can be biased. It is estimated that approximately 30%
of postmenopausal women in America take some form ofHRT (Barrett-Conner et aI.,
2000). Noncompliance to HRT is largely due to possible side effects ofHRT. Side
effects include, but are not limited to, increased risk of endometrial and breast cancer,
thrombosis and irregular menstrual bleeding (Lobo, 1995; Notelovitz, 1989). These side
effects are very disturbing for some women; therefore, leaving them seeking other ways
to decrease CHD and relieve menopausal symptoms.
SELECTIVE ESTROGEN RECEPTOR MODULATORS
Selective estrogen receptor modulators (SERMs) produce tissue-specific agonist
or antagonist activity on estrogen receptors. There are two generations of SERMs:
tamoxifen and raloxifene. The first generation SERM, Tamoxifell, was originally used to
treat breast cancer since it is an estrogen antagonist in the breast; however, it is an
estrogen agonist in the endometrium possibly causing endometrial cancer. Tamoxifen
and raloxifene have shown similar results relating to CHD risk (Anthony et aI., 2001).
Raloxifene has shown beneficial effects on LDL-cholesterol, Lp(a) and homocysteine.
SERMs have shown decreases in LDL-cholesterol and no change in TG or HDL, unlike
HRT, which can increase TG and decrease HDL (Walsh et aI., 1998; Walsh et aI., 2000).
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SERMs can have many adverse reactions such as: increasing risk of endometrial cancer,
venous thromboembolic events, stroke, and increasing menopausal symptoms such as hot
flashes (Anthony et aI., 2001). After considering these risks, many postmenopausal
women seek natural ways with fewer side effects to treat menopausal symptoms. -
PHYTOESTROGENS
Phytoestrogens have shown beneficial effects on CHD risk, menopausal
symptoms, osteoporosis and certain types of cancer. Phytoestrogens are naturally
occurring plant compounds that are similar in function and structure to estradiol (E2). It
is thought that the mechanism phytoestrogens use is more related to SERMs than HRT,
as far as producing estrogenic and antiestrogenic activity (Anderson et aI., 1999). The
most common phyloestrogens are isoflavones, lignans and coumestans. Isoflavones
include genistein and daidzein. Coumestrol is the most important coumestan and it is
commonly found in alfalfa. The major lignans are enterolactone and enterodiol, which
are produced by colonic bacteria from their dietary precursors, which undergoes
enterohepatic circulation. Grains are a good source of lignans. Commonly consumed
sources of phytoestrogens are cereal, beans, flaxseed, fruits and vegetables (Adlercreutz
& Mazur, 1997; Humfrey, 1998).
The isoflavone class of phytoestrogens is the most extensively researched class of
phytoestrogens. Genistein and daidzein make up the majority of isoflavones, which
appear to have estrogenic properties. Activity of estrogen depends on the affinity of
estrogen binding to estrogen receptors. Genistein and daidzein bind to estrogen receptors
with less affinity when compared to E2; therefore, they produce a weak estrogenic effect.
17
Antiestrogenic effects of isoflavones are possibly due to competitive inhibition of the
estrogen receptor (Adlercruetz et aI., 1995).
One of the most common sources of isoflavones is the soybean. Intake of dietary
phytoestrogens by postmenopausal women was studied in the Framingham Offspring
study. Kleijn et aI. (2001) found that dietary lignin intake was much higher than dietary
isoflavone intake. Asian populations consume about 20-50 grams of soy protein per day,
which is about 20-80 mg of phytoestrogens per day. The total intake found in the
selected population from the Framingham Offspring study was less than 1 mg per day.
The Food and Drug Administration in the United States has allowed food
companies to make the health claim that soy protein reduces the risk of heart disease by
lowering cholesterol levels (Setchell & Radd, 2000). An average intake of 47 gld of soy
protein in humans has been found to decrease TC an average of 9°~, LDL-cholesterol by
13% and TG by 10%. Greater improvements on lipid profiles were found in participants
who had higher cholesterol levels at the beginning of the study (Anderson et aI., 1995).
Possible mechanisms of the hypocholesterolemic effects of phytoestrogens are:
increasing bile acid excretion therefore increasing LDL-cholesterol removal, creating a
hyperthyroid state, and increasing removal of LDL-cholesterol by hepatocytes by altering
hepatic metabolism (Forsythe, 1995). Evidence supporting a decrease in LDL-
cholesterol has been seen, but less effect has been seen on HDL-cholesterol levels
(Anderson et aI., 1995).
Phytoestrogens can possibly be a better alternative to drug therapy to decrease
CHD due to fewer side effects. Increased risk of breast and uterine cancer has been
associated with HRT unlike with phytoestrogens. In fact phytoestrogens have been
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associated with a decrease in some cancers; however, it is still not clear whether
phytoestrogens impact honnone sensitive cancers and significantly improve lipid profiles
(Nebres & Mark, 1996).
DRIED PLUMS
Dried plums (Prunus domestics L.) are an excellent source of fiber, potassium,
iron, folic acid, and phytochemicals (Stacewicz-Sapuntzakis et aI., 2001). Dried plums
recently ranked the highest in antioxidant activity using the automated radical absorbance
capacity (ORAC) assay (McBride, 1999). Another study ranked plums second to
strawberries in antioxidant capacity using the ORAC assay (Wang et aI., 1996).
Dried plums, also known as prunes, carry the stereotype of having an increased
laxative effect; however, regular consumption has shown that an excessive laxative effect
does not occcur. Dried plums can actually be beneficial in maintaining regular bowel
habits. The minor laxative effect dried plums might have is possibly due to the high fiber
or sorbitol content (Stacewicz-Sapuntzakis et aI., 2001). One study evaluated 48 men
consuming 100 g of dried plums per day for four weeks. Results showed the fecal wet
and dry weights increased significantly after eating the dried plums. However, this did
not result in diarrhea because the water content did not change between treatment groups
(Tinker et aI., 1991).
Dried plums are used in India to treat leukorrhea, irregular menstruation and
weakness following miscarriage (Fang et aI., 2002). Animal and human studies have
shown beneficial effects of dried plums on bone, cardiovascular disease and management
of blood glucose levels for diabetics (Arjmandi et aI., 2001; Arjmandi et aI., 2002; Lucas
et aI., 2000; Stacewicz-Sapuntzakis et aI., 2001; Tinker et aI., 1991; Tinker et aI., 1994).
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Polyphenolic compounds are believed to have antioxidant properties. The most
predominant phenolic compounds in dried plums are neochlorogenic acid and
chlorogenic acid. The phenolic compounds in dried plums have been found to inhibit in
vitro oxidation of human LDL-cholesterol (Donovan et aI., 1998; Meyer et aI.,--1998).
Dietary antioxidants are beneficial by preventing oxidative damage that can occur in the
body. By preventing or decreasing oxidative stress within the body one can possibly
decrease their risk of cancer, heart disease and other age-related diseases (Fang et a!.,
2002). By inhibiting oxidation of cholesterol and fatty acids this can decrease
atherosclerotic plaque formation; therefore, decreasing CHD risk. Plums are also a good
source of copper, which is needed for oxidative and anti-oxidative enzymes to function
properly; if balance is not maintained, unfavorable lipid levels can occur (Stacewicz-
Sapuntzakis et aI., 2001).
The cardiovascular benefits of dried plums involve improving hypertension and
cholesterol levels. Dried plums contain 745 mg of potassium per 100 g (Food Processor
version 7.50, ESHA Research, Salem, OR). Potassium helps maintain proper electrolyte
balance and acts like a muscle relaxant, which can help prevent or control hypertension
(McDonald et aI., 1998). Not only do dried plums have the potential to alleviate high
blood pressure but also hypercholesterolemia (Lucas et aI., 2000; Tinker et aI., 1991).
Dried plums are an excellent source of dietary fiber, both insoluble and soluble.
Dried plums contain about 7 g of dietary fiber per 100 g (",,3 g soluble fiber and ~4 g
insoluble fiber) (Food Processor version 7.50, ESHA Research, Salem, OR). Various
studies and methods of fiber extraction from dried plums resulted in varying amounts of
different amount of fibers in dried plums. Studies have stated that 40 to 80% of dried
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plum fiber is pectin (soluble fiber) with the rest mostly being cellulose and hemicellulose
(insoluble fiber). Pectin, a soluble fiber, is belleficial in improving lipid profiles. Tinker
et al. (1994), performed an animal study comparing different doses of fiber types and the
effect on hyperlipidemic rats. Plasma LDL and liver cholesterol decreased when animals
were fed pectin or dried plum; however, it was found not to be dose dependent. A similar
study involving men found dried plums significantly lowered plasma LDL-cholesterol.
Fiber is believed to decrease plasma cholesterol by increasing bile acid secretion (Tinker
et aI., 1991). Research studies involving dried plums are limited; therefore, research
using dried plums is greatly needed.
DRIED APPLES
Dried apples like dried plums are also an excellent source of fiber and
antioxidants. However, research is limited using apples to lower cholesterol levels.
Wang et al. (1996) analyzed 12 fruits and five commercial fruit juices total antioxidant
activity using the ORAC assay. When they analyzed the wet weight (edible portion) and
dry weight of the fruits, apples ranked ninth out of 12 fruits; however, plums ranked
second. This leads us to the conclusion that apples appear to have an antioxidant effect,
which can be protective against heart disease.
One study fed healthy rats different doses of apple pectin and orange pectin for
three weeks. They examined cholesterol concentrations in feces, serum, and liver. Their
findings demonstrated a significant decrease in hepatic cholesterol in all pectin fed
groups. Cholesterol concentration increased significantly only in the high dose apple and
orange pectin fed groups. However, serum cholesterol decreased significantly only in the
apple pectin fed groups (Gonzalez et aI., 1998). Another animal study compared the
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effect of two different dehydrated apple products on serum and liver lipids. After feeding
the hamsters a high cholesterol, high fat diet the intervention of dehydrated apple pulp or
dehydrated apple pomace was initiated. After two months both apple products decreased
serum TC and TG by 40-70%. Hepatic cholesterol content decreased in both groups;
however, only the apple pulp decreased TG. Even after six months on treatment the
apple pulp continued to decrease cholesterol and TG in the serum and liver (Bobek et aI.,
1990). One human study included 25 men with mild hypercholesterolemia who drank 20
ounces of apple juice supplemented with fiber and 200 mg vitamin C. The fiber
supplement consisted of apple fiber and gum arabic. The random, crossover study lasted
for 12 weeks with no washout period. Fiber and vitamin C intake significantly increased
among subjects during the study and dietary cholesterol intake slightly, but significantly
decreased during the study. The fiber supplemented juice significantly decreased TC and
LDL-cholesterol (Mee & Gee, 1997). Other apple products have also shown to decrease
LDL oxidation in vitro (Pearson et aI., 1999). Apples have been found to contain many
bioactive constituents; however, we do not know exactly which component possibly
exerts this possible cardioprotective effect (Justesen et aI., 1998, van der Sluis et aI.,
2001; Wang et aI., 1996). These studies demonstrate that more researcll on apples and





Fifty-eight postmenopausal women, who had not been on HRT for at least one
year, were recruited though mass mailings and newspaper advertisements from the
Oklahoma State University Campus, Stillwater, Oklalloma and communities nearby. The
age of the participants was 54.3 ± 5.9 (mean ± SEM) years old. Postmenopausal status
was detennined by at least one year of amenorrhea. Exclusion criteria consisted of: less
than 2 years or greater than 10 years postmenopausal; bone disorders (osteomalacia,
osteoporosis, unexplained stress fractures), cancer, diabetes mellitus, gastrointestinal or
chronic digestive disorders, hypertension controlled with thiazide diuretics, active liver
disease, parathyroid disorders, renal disease or problems, thyroid problems, pelvic
inflammatory disease, and/or endometrial polyps. Women who smoked;;::: 20 cigarettes
per day were also excluded. Participants would not qualify for the study if they currently
took or have taken these medications since onset of menopause: glucocorticoids,
anabolic steroids, anticonvulsants, calcitonin, bisphosphonates, estrogens, oral
contraceptives, HRT, or if they had been on thyroid hormones for less than six months.
The primary reason for this study was to examine the effects of dried plums on bone.
Because CHD was not the primary reason for the study, women taking lipid-altering
medications were not excluded.
Participants were initially screened by a telephone interview. Qualified
participants were then asked to attend their first appointment where they signed a consent
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form after reviewing and discussing a description of the study. Subjects were asked to
attend five appointments. Three appointments took place at the Human Environmental
Sciences laboratories, Oklahoma State University (OSU). The other two appointments
were held at Cimarron Women's Clinic in Stillwater, Oklahoma. Twenty women
dropped out of the study, because of time constraints and gastrointestinal problems,
leaving 38 women completing the study. Participants were asked to maintain their
normal physical and dietary habits during the study. The OSlJ Institutional Review
Board approved the study.
EXPERIMENTAL DESIGN
This study was a randomized, controlled trial in which qualified subjects were
assigned to receive either dried plums or dried apples daily for three months. Each
participant consumed 100 grams of dried plums supplied by the California Prune Board,
which were vacuum-sealed into individual packages. Dried apples were packaged at
OSU into 75-gram vacuum-sealed packages. Study participants were asked to take into
consideration the extra caloric consumption, from the study food, and adjust their diet
accordingly. The dried fruit regimens were dispensed to the participants on a monthly
basis. Participants returned any unused dried fruits and a self-recorded log at the end of
each month to determine compliance. Seventy-five grams of dried apples was chosen as
the control because it is comparable to 100 grams of dried plums in calories,
carbohydrates, fat and fiber as analyzed by food analysis software (Food Processor
version 7.50, ESHk Researc~ Salem, OR). Nutrient analysis of dried plums and dried
apples is given in Table II.
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DIETARY ASSESSMENT
All participants answered questions regarding their medical and nutrition histories
at the beginning of the study. i\t the beginning and end of the study, a registered dietitian
interviewed the subject and filled out a seven-day food frequency questionnaire
(Thompson & Byers, 1994). Foods were then coded and analyzed by food analysis
software (Food Processor version 7.50? ESHA Research? Salem, OR).
ANTHROPOMETRIC MEASUREMENTS AND BODY FAT ANALYSIS
At baseline each participant's age? weight? height, waist circumference, hip
circumference, wrist circumference, knee height and body fat percentage were obtained
(Table I). Weight was determined using a standardized weighing scale (Healthometer,
Continental Scale Corporation, Chicago, IL). Participants weighed in street clothes
without shoes. Height was obtained using a stadiometer (Shorr Productions, Olney, MD).
BMI was then calculated using the Quetelet's index equation:
BMI =::: weight (kg)/ height2 (m)
A trained staff member took waist and hip measurements using a measuring tape. Waist
to hip ratio was calculated using waist and hip circumferences. Body fat was estimated
by bioelectric impedance (Jackson et aI., 1988) (Biodynalnics Model 310, Biodynamics
Corp., Seattle, WA).
BLOOD COLLECTION AND PROCESSING
A pWebotomist obtained a fasting 20 ml venous blood sample from each
participant at baseline and at the end of three months. Blood samples were drawn into
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nonheparinized vacutainer tubes and placed in ice. Samples were centrifuged at 2000g
for 15 minutes at 4°C. Serum and plasma were then aliquoted into smaller
microcentrifuge tubes and stored at -20°C. All blood samples were analyzed at the same
time at the completion of the study.
ANALYSIS OF SERUM LIPIDS AND LIPOPROTEINS
A Cobas-Fara II Clinical Analyzer (Monclair, NJ) was used to analyze total
cholesterol, HDL, Lp(a), apo A-I, apo B, TG, and CRP. Calibration of the Cobas-Fara II
Clinical Analyzer was performed before each test using a Roche Calibrator (Roche
Diagnostic Systems; Somerville, NJ; Nutley, NJ; Branchburg, NJ) with the exception of
Lp(a) and CRP. Lp(a) and CRP were calibrated using SPQ Calibration sets (Stillwater,
Minnesota). BioRad QCS Levelland Level 2 controls were used in all tests except apo
A and apo B, where Roche Apolipoprotein Standard was used.
The process of quantitative measurement of total cholesterol occurs by cholesterol
esterase acting upon cholesterol esters resulting in free cholesterol and fatty acids. The
free cholesterol is then oxidized by cholesterol oxidase forming hydrogen peroxide,
which is combined with 4-aminoantipyrine and phenol resulting in quinoneimine. The
cholesterol concentration was measured photometrically at 500 nm. A direct relationship
occurs between the increase in absorbance and cholesterol amOllnt (Roche Diagnostics,
Branchburg, NJ).
HDL-cholesterol concentrations were determined directly by adding
phosphotungstic acid and magnesium chloride to serum samples and centrifuging leaving
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the HDL fraction in the supernatant (Roche Diagnostic Systems; Nutley, NJ). The
following equation was used to calculate LDL-cholesterol (NCEP, 1993):
LDL == total cholesterol- [HDL-cholesterol + (TG/5)]
Triglycerides are hydrolyzed by lipoprotein lipase fanning glycerol and fatty
acids. Adenosine triphosphate phosphorylates glycerol with the action of glycerol kinase
resulting in glycerol-3-phosphate. Oxidation occurs fonning dihydroxyacetone
phosphate and hydrogen peroxide. A quinoneimine complex fOnTIS after hydrogen
peroxide reacts with 4-chlorophenol and 4-aminophenazone. This complex was read at
490-550nm. As absorbance increases as the concentration of triglycerides
proportionately increases (Roche Diagnostics; Nutley, NJ).
Apo A-I and apo B were measured by' forming a precipitate with a specific
antiserum from sheep and rabbits respectively (Roche Diagnostics; Somerville, NJ).
Samples were measured at 340 nm after a set amount of time. Apo A-I and apo B levels
were proportional to the degree of turbidity.
Quantitative determination of Lp(a) was performed by automated
immunoprecipitin analY'sis (DiaSorin Inc.; Stillwater, MN). A polymeric enhancer was
added to the samples prior to incubation. Antiserum was then added to the samples and
insoluble complexes started forming, resulting in increased turbidity. Another incubation
period occurred and Lp(a) was measured by tile amount of absorbance of the solution.
CRP was determined by immunoprecipitin analysis (DiaSorin Inc.; Stillwater,
MD). Antiserum was added to samples after an initial incubation period. Insoluble
complexes fonn, which increased turbidity. Another incubation period of about five
minutes occurred and the absorbance of the solution was measured.
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DATA COLLECTION AND STATISTICAL ANALYSES
A trained graduate assistant entered data from the questionnaires and serum
analyses into a spreadsheet. Data were analyzed using SAS (version 8.0, SAS Institute,
Cary, NC). PROC MIXED was used to calculate the least square means and analysis of
variance (ANOVA). The least square mean ± standard error was reported. A p value





Demographics of participants are given in Table I. Fifty-eight women enrolled in
the study with 38 completing the study (18 on dried plum regimen and 20 on the dried
apple regimen). Nine women quit the study due to noncompliance, one women thought it
was too time consuming, four women dropped out because of medical conditions, and
one woman quit for personal reasons. Five women in the dried plum group did not finish
because of gastrointestinal problems: one stated loose stools and another stated increased
flatulence, and two said the dried plums caused constipation and another stated
abdominal pain. The women who completed the study stated that the study food was a
reasonable amount to be consumed on a daily basis.
NUTRIENT !NTAKE
The 7-day food frequency questionnaire analysis revealed no significant
differences in food intakes between treatment groups or between baseline and final
(Table III). This questionnaire included the dried plum and dried apple supplement.
There were slightly higher intakes of total energy, protein and carbohydrate in the dried
plum group at the end of the study in comparison with their baseline values, but they
were not significantly different. Both groups also appeared to slightly increase their fiber
intake during the study.
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DEMOGRAPHICS AND ANTHROPOMETRIeS
Table I gIves the demographic and anthropometric characteristics of the
participants. The mean age for the dried plum group was 53.6 ± 1.6 and the dried apple
group's mean age was 55 ± 1.2 years. Years since menopause was 7.9 ± 1.8 and 9.1 ±
1.8 for the plum and apple groups respectively. a significance was found between the
two groups at baseline for age, years since menopause, weight, BMI, waist to hip ratio or
body fat percentage. There were no significant changes in weight, BMI or waist to hip
ratio in either group, when baseline and final visit were compared. There were no
significant changes in body fat percentage in either group; however, the dried apple group
demonstrated a trend (P == 0.0551) of decreasing body fat percentage.
SERUM ANALYSES
Serum analyses were ran only on the participants that completed the study.
Consumption of dried plums resulted in a significant increase in TC (P < 0.05) ( able
IV), while the dried apples demonstrated a trend (P < 0.07) in lowering Te. LDL-
cholesterol significantly decreased and HDL-cholesterol significantly decreased in the
dried apple regimen, but no difference was found in the dried plum regimen. No
significance was found in TG, apo A-I, apo B, Lp(a) or CRP. However, a trend (P ==
0.07) was found in increasing TG with the dried plum regimen. Mean changes from
baseline values in serum lipid parameters and body fat percentage after 3-months of dried




The hypocholesterolemic effects of dried plums have not been adequately
investigated. To our knowledge, there is one published human study (Tinker et aI., 1991)
which has shown the effectiveness of dried plums in lowering serum total cholesterol in
men. The present study is the first trial to examine the hypocholesterolemic properties of
dried plums in postmenopausal women. We conducted this study because the findings of
our earlier animal study (Lucas et aI., 2000) demonstrated the favorable effects of dried
plums on lipid profiles in ovarian hormone deficiency. In that study (Lucas et aI., 2000),
ovariectomized rats were given diets containing either 5% or 25% dried plums for 45
days. Although both dried plum diets were effective in preventing the ovariectomy-
induced rise in serum total cholesterol, only the 25% dried plum diet was able to
significantly prevent the rise in serum total cllolesterol.
Though elevated serum total cholesterol is a risk factor for the development of
CHD, measurement of other lipoprotein particles may be necessary to adequately assess
a person's risk for CHD (Branchi et aI., 1994). It is well recognized that increased total
cholesterol, LDL-cholesterol, TG and decreased HDL-cholesterol increase a persons'
CHD risk. Other parameters that can be evaluated include apo A-I, apo B, Lp(a), CRP
and body fat percentage (Kim et aI., 2000; Tremollieres et aI., 1999).
Our findings that dried plum regimen increased serum cholesterol contradict
Tinker and colleagues' results (1991). However, in the current study we cannot offer an
explanation as to why women who consumed dried plums experienced an increase in
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their serum total cholesterol. Nonetheless, we can speculate that this unexpected increase
in total cholesterol might have been due to high sugar content of dried plums, as sucrose
has been shown to increase serum total cholesterol (Stacewicz-Sapuntzakis et al., 2001).
Our findings that dried plums tended to increase TG are in agreement with Tin er and
colleagues~ findings (1991) where they also noticed an increasing trend in serum TG. Our
results lead to the question as to whether dried plunls' beneficial effects on bone in
postmenopausal women (Arjrnandi et al., 2002) outweigh the risk of increasing serum
total cholesterol. Dried plums are a rich source of dietary fiber and antioxidants. Both
dietary fiber and antioxidants have been demonstrated (Donovan et aI., 1998; Stacewicz-
Sapuntzakis et al., 2001; Walk et aI., 1999) to be effective in decreasing cholesterol and
risk of CHD. Therefore, we cannot totally rule out the beneficial effects of dried plums in
spite of our negative findings.
However, our comparative control dried apple regimen lowered (P ~ 0.066) total
cholesterol concentration in comparison with corresponding baseline values. The apple
regimen also significantly (P < 0.05) reduced serum LDL-cholesterol. More interestingly,
dried apples increased (P < 0.02) serum HDL-cholesterol concentrations. These favorable
effects of dried apples on lipid profiles may be in part due to apples' pectin and
antioxidant contents. Decreasing LDL-cholesterol and increasing HDL-cholesterol is
considered to be cardioprotective; therefore, CHD risk could possibly decrease among
postmenopausal women using dried apples. Apples have been reported to have beneficial
effects on cholesterol levels in animals and humans (Bobeck et aI., 1990; Mee and Gee,
1997). Gonzales et al. (1998) conducted a study feeding rats 2.5% or 50/0 apple pectin,
orange pectin or a control for 3 weeks. Their study found that hepatic cholesterol
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concentrations were significantly decreased in all groups; however, serum total
cholesterol only significantly decreased in the apple pectin fed rats.
Another interesting point in the current study is that postmenopausal women who
consumed dried apples experienced a decrease in p,ercent body fat. Postmenopausal
women usually have increased central adiposity and hence the findings of our study if
confirmed in future studies with larger sample size should have public health
implications.
In summary, the results of the present study show that even though dried plums
have shown the possibility of decreasing bone loss associated with menopause it might
increase serum total cholesterol, a risk for CHD. In contrast, dried apples, as expected
have not only lowered total- and LDL-cholesterol but at the same time elevated serum
HDL-cholesterol, confirming the notion that apples are good fruits for health promotion.
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Dried Apples Dried Plums
Base Final pb Base Final pb
Age (years) 55 ± 1.2 ---- ---- 53.6±1.6 ---- _.....-
Time since
menopause (years) 9.1 ± 1.8 ---- ---- 7.9 ± 1.8 ---- ----
Weight (lbs) 163.9 ± 7.6 164 ± 7.6 0.40 171.6±8.0 172.9 ± 8.0 0.32
BMI (kg/m2)b 28.3 ± 1.3 28.5 ± 1.3 0.40 28.9 ± 1.3 29.1±1.3 0.31
Waist/hip ratio 0.81 ± 0.02 0.81 ± 0.02 0.81 0.81 ± 0.02 0.80 ± 0.02 0.24
Body Fat (%)C 37.6 ± 1.1 36.7±1.1 0.06 35.6± 1.0 36.2 ± 1.2 0.20
aValues are mean ± SE; n=18 for dried plum regimen, n=20 for dried apple regimen.
bBMI - body mass index
CBody fat percentage determined by bioelectric impedance (Biodynamics Model 310).
TABLE I
Com onent Dried Plums ( er 100 )
Concentration of selected nutrients in dried lums and dried a lesa
Calories 239.0
Protein (g) 2.61
Dietary Fiber (g) 7.10
Soluble Fiber (g) 2.98
Insoluble Fiber (g) b 4.12
Total Fat (g) 0.43 0.52
Saturated Fat (g) 0.07 0.04
Monounsaturated Fat (g) 0.02 0.34
Polyunsaturated Fat (g) 0.13 0.11
Total Sugar 58.15 42.95
Vitamin A (ill) 60.75 1987.0
A-Carotenoid (RE) 6.00 199.0
A-Beta Carotene (meg) 24.48 1075.0
Niacin (Vitamin B3) (mg) 0.51 1.96
Vitamin B6 (mg) 0.21 0.26
Vitamin B12 (meg) 0 0
Vitamin C (mg) 1.65 3.3
Vitamin E (ill) 4.00 2.16
Folate (meg) 0.75 3.70
Potassium (mg) 480.0 745.0
Iron (m ) 1.5 2.48




Daily nutrient intake calculated from 7-day food frequency questionnaires of women
before and after 3-month supplementation with 100 g dried plums or 75 g dr'ed apples
d '1 aally
Daily intake Dried Apples Dried Plums
Before After Before After
Treatment Treatment Treatment Treatment




Protein 73.8 ± 20.7 64.7 ± 18.1 62.5 ± 13.4 71.7 ± 20.9
Carbohydrates 239 ± 69 252 ± 68 204 ± 47 279 ± 62
Dietary fiber 19.2 ± 6.8 24.0 ± 7.3 19.3 ± 6.0 26.9 ± 8.7
Total fat 56.9 ± 18.4 62.0 ± 28.4 59.9 ± 20.5 70.1 ± 31.6
Saturated fatty
19.4 ± 6.8 20.0 ± 9.8 21.5±8.2 23.8 ± 9.6
acids
Polyunsaturated
10.1 ± 3.9 10.8 ± 5.2 10.5 ± 4.6 13.0 ± 8.8
Fatty acids
Alcohol (g) 1.4 ± 2.6 2.3 ± 3.4 4.8 ± 9.0 3.0 ± 7.2
Vitamins
Vitamin A (IV) 12592 ± 9430 12830 ± 7044 15526 ± 15523 15961 ± 11978
Vitamin C (mg) 116 ± 79 107 ± 62 122 ± 79 135 ± 87
Vitamin D (IV) 165 ± 114 127 ± 78 121 ± 83 117 ± 60
Vitamin E (ill) 9.3 ± 4.2 10.5± 5.6 9.5 ± 2.9 14.4± 14.0
Vitamin K (J.lg) 68.7 ± 59.8 94.2 ± 82.4 121.8 ± 96.7 101.1 ± 64.9
Minerals (mg)
Calcium 941 ± 455 710 ± 275 695 ± 273 803 ± 266
Iron 13.4 ± 6.4 13.3 ± 4.2 12.2 ± 2.8 16.3 ± 4.5
Magnesium 287 ± 77 286 ± 116 280 ± 69 353 ± 137
Phosphorus 1224 ± 364 1069 ± 335 1049 ± 272 1207 ± 401
Potassium 3029 ± 1086 2883 ± 902 2714 ± 706 3399 ± 940
Zinc 10.2 ± 3.2 9.0 ± 2.8 8.9 ± 2.0 11.0±4.2
aValues are mean ± SE; n= 20 for dried apple regimen and 18 for dried plum regimen.
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TABLE IV
atd . dt tthEf£ t f3ec 0 -mon supp emen a Ion WI ne p urns or rle app es on serum parame ers
Dried Apples Dried Plums
Base Final pb Base Final pb
Serum measurement
Total cholesterol 236.95 ± 8.49 230.15 ± 8.49 0.066 214.78 ± 8.95 223.44 ± 8.95 0.028
(mg/dL)
HDL-cholesterol 37.55 ± 3.07 41.15 ± 3.07 0.016 44.31 ± 3.24 42.08 ± 3.24 0.146
(mg/dL)
LDL-cholesterol 158.32 ± 8.04 149.40 ± 8.04 0.045 140.62 ± 8.48 145.69 ± 8.48 0.269
(mg/dL)
Triglycerides 205.42 ± 25.73 198.0 ± 25.73 0.618 149.28 ± 27.13 178.33 ±27.13 0.070
(mg/dL)
Apolipoprotein A-I 153.19 ± 7.73 163.6 ± 7.61 0.138 155.03 ± 8.33 161.33 ± 8.02 0.401
(mg/dL)
Apolipoprotein B 129.0 ± 5.59 122.18 ± 5.59 0.256 113.94 ± 5.89 115.33 ± 5.89 0.825
(mg/dL)
Lipoprotein a 47.27 ± 14.18 54.91 ± 14.14 0.134 36.24 ± 14.53 30.15 ± 14.53 0.230
(mg/dL)
C-reactive protein 6.77±1.14 6.79±1.17 0.987 5.09 ± 1.24 4.39 ± 1.20 0.647
(mg/L)
Estradiol (pg/mL) 8.91 ± 2.42 9.33 ± 2.5 0.793 11.02 ± 2.58 9.48 ± 2.56 0.344
Estrone (pg/mL) 21.83 ± 3.84 22.37 ± 3.84 0.815 24.07 ± 4.09 21.85 ± 4.05 0.379
aReported values are mean ± SE; n=20 for dried apple regimen and 18 for dried plum regimen.
bP values represent comparison within groups between baseline and corresponding [mal values after treatment.
FIGURE I
Mean changes from baseline values in serum lipid parameters and body fat percentage
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Compared with dried plums, dried apples significantly reduced total cholesterol
(TC; P < 0.01), LDL-cholesterol (P < 0.05), and body fat percentage (P < 0.05). Dried
apples significantly increased HDL-cholesterol (P < 0.01) and Lp(a) (P < 0.05). A trend
was also found with dried apples decreasing triglycerides (P < 0.1). *Unit for TC, LDL,
HDL, TG, Apo A-I, Apo B, and Lp(a) is mg/dL. Unit for CRP is mg/L and body fat is
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